title: NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes.
abstract: Acute myeloid leukemia with mutated nucleophosmin (NPM1m+AML) is a heterogeneous entity. We investigated whether NPM1m+AML with monocytic or myeloid differentiation have distinct immunophenotype. The study included 160 NPM1m+AMLpatients and 178 AML patients without NPM1 mutation and recurrent cytogenetic abnormality (NPM1wt-AML). We analyzed the immunophenotype by flow cytometry. NPM1 mutation was detected by PCR. Compared with NPM1wt-AML patients, NPM1m+AML patients showed higher positive rates of CD33 and CD9 and lower positive rates of CD34, HLA-DR, CD7, CD15 and CD117 (all P<0.05). HLA-DR, CD64, CD14, CD11b, CD15, CD4, CD9 and CD10 were higher (P<0.001) and CD117 was lower (P<0.01) in monocytic NPM1m+AML compared with myeloid NPM1m+AML. Similar rates of lymphoid antigen (CD19, CD2, and CD7) and myeloid antigen (CD13, CD33) positivity were detected in monocytic and myeloid NPM1m+AML. Compared with NPM1wt-AML, CD34 expression was lower both in myeloid and monocytic NPM1m+AML subgroups, although HLA-DR was lower in NPM1m+AML compared with NPM1wt-AML only in myeloid subgroup. Comparisons of NPM1m+AML and NPM1wt-AML showed no differences in monocyte-associated markers such as CD14 and CD11b in myeloid and monocytic subgroup. Myeloid NPM1m+AML correlated with the female gender (P=0.001), lower WBC counts (P=0.04) and higher WT1 transcripts (P=0.006) compared with monocytic NPM1m+AML.These results suggested monocytic and myeloid-derived NPM1m+AML exhibit distinct immunophenotypes.
authors.affiliation: Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China. yrliu163@163.com
authors.forename: Yan-Rong
authors.initials: YR
authors.lastname: Liu
authors.forename: Hong-Hu
authors.initials: HH
authors.lastname: Zhu
authors.forename: Guo-Rui
authors.initials: GR
authors.lastname: Ruan
authors.forename: Ya-Zhen
authors.initials: YZ
authors.lastname: Qin
authors.forename: Hong-Xia
authors.initials: HX
authors.lastname: Shi
authors.forename: Yue-Yun
authors.initials: YY
authors.lastname: Lai
authors.forename: Yan
authors.initials: Y
authors.lastname: Chang
authors.forename: Ya-Zhe
authors.initials: YZ
authors.lastname: Wang
authors.forename: Dan
authors.initials: D
authors.lastname: Lu
authors.forename: Le
authors.initials: L
authors.lastname: Hao
authors.forename: Jin-Lan
authors.initials: JL
authors.lastname: Li
authors.forename: Ling-Di
authors.initials: LD
authors.lastname: Li
authors.forename: Bin
authors.initials: B
authors.lastname: Jiang
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000276:immunology* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations; D005260:Female; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000276:immunology* / Q000473:pathology; D009154:Mutation / Q000235:genetics*; D022423:Myeloid Cells / Q000276:immunology* / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D006684:HLA-DR Antigens; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin